Business Wire

Geneva Business School Celebrates 30 Years of International Excellence at Its Graduation Ceremony in Barcelona

7.7.2025 10:29:00 CEST | Business Wire | Press Release

Share

Geneva Business School held its traditional graduation ceremony this week in Barcelona, marked this year by a very special occasion: the institution’s 30th anniversary. With more than three decades of experience shaping business leaders in a globalized environment, Geneva Business School has consolidated its practical and international teaching model, inspired by Swiss academic standards, as a key reference in the Spanish educational ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250704769866/en/

“Our students are entering a world marked by complex geopolitical challenges, a world in urgent need of a new style of leadership. Their education at Geneva Business School has instilled in them a deep understanding of what it means to lead with integrity on a global stage,” said Mrs. Nicola Jackman, Global Head of Academics at Geneva Business School, during her speech at the ceremony.

With campuses in Barcelona and Madrid, Geneva Business School brings Swiss excellence into a multicultural environment. Its learning model is based on project-based learning, where students apply real-world skills and tools to business projects from the very beginning of their studies. Furthermore, its faculty is made up of active professionals with experience in key sectors such as finance, marketing, consulting, and entrepreneurship, ensuring a curriculum closely aligned with real market challenges.

This year's graduation ceremony featured the special participation of two prominent figures in the business world, who shared with graduates their insights and advice on how to face their professional futures successfully. To guide students in this new chapter, Agustín Gómez, co-founder of Wallapop, and Francisco Campo, president of Planet Future Foundation, offered valuable advice aligned with the school’s philosophy.

“These are the two simple things I want to share with my children—and with you—: first, knowing your greatest weakness will save you a lot of suffering. Second, discovering your natural talent will make it easier to find the places, projects, and people where you can shine,” said Agustín Gómez during his keynote speech.

Francisco Campo, for his part, emphasized the importance of driving a positive and sustainable impact in the business and social environment, calling on graduates to apply their knowledge with a forward-thinking, committed, and transformative vision. “I’m honored to take part in this year’s ceremony, inspiring the graduating students and helping them face their fears as they embark on this new stage of their lives,” Campo stated.

The more than 168 graduates of this year’s class come from over 40 different nationalities, reflecting the global character of the institution. Geneva Business School has become a bridge between international talent and the European business landscape. In this sense, the impact of the Swiss model is particularly relevant: the school’s importance within the Spanish context becomes clearer when analyzing the country’s capacity to attract and retain talent. According to the latest World Talent Ranking from the Institute for Management Development (IMD), which evaluates 64 countries, Spain ranks 32nd, far behind Switzerland, which once again tops the list. This ranking clearly shows that while Spain continues to struggle in becoming a talent hub, the Swiss model stands out as a differentiator.

In this context, Geneva Business School offers a clear solution: international-quality education from Spain, with a Swiss methodology and direct connection to the market. A strategic combination to prepare leaders capable of operating in global environments without having to leave the country to access top-tier education.

In addition to classroom instruction, the school promotes close collaboration with companies and organizations, encouraging internships, expert-led workshops, and activities that connect the academic world with the realities of the labor market. This dynamic allows students to integrate from day one into demanding and constantly evolving environments.

Another key pillar of Geneva Business School is its commitment to developing talent through motivation, creativity, and entrepreneurship. Students are encouraged to explore their potential, discover their purpose, and apply their skills in real-life contexts. In line with this mission, the event featured contributions from leaders in social impact and tech entrepreneurship.

The school’s mission goes beyond training graduates with technical competencies: it aims to have a positive impact on future business leaders by combining a rigorous methodology with personalized attention, high-quality resources, and a clear focus on professional success.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250704769866/en/

Contacts

Laia González: lgonzalez@lfchannel.com
+34 671745781

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye